---
title: "Weekly Recap | AIM ImmunoTech -11.92%, patent estate adds oncology and Long COVID coverage"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298095225.md"
description: "AIM ImmunoTech (AIM) fell 11.92% this week to close at $0.2276. Over the same period the S&P 500 edged up 0.09%, leaving the stock about 12.01 percentage points behind the benchmark. Monday opened at $0.3709, hit an intraday low of $0.2015 and finished at $0.2260, with weekly amplitude at 45.78%. The next four sessions settled into a tighter range, with closes between $0.2276 and $0.2360."
datetime: "2026-09-05T06:04:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298095225.md)
  - [en](https://longbridge.com/en/news/298095225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298095225.md)
generator: "portal-rs"
---

# Weekly Recap | AIM ImmunoTech -11.92%, patent estate adds oncology and Long COVID coverage

## The Week

AIM ImmunoTech (AIM) fell 11.92% this week to close at $0.2276. Over the same period the S&P 500 edged up 0.09%, leaving the stock about 12.01 percentage points behind the benchmark. Monday opened at $0.3709, hit an intraday low of $0.2015 and finished at $0.2260, with weekly amplitude at 45.78%. The next four sessions settled into a tighter range, with closes between $0.2276 and $0.2360.

## Key Events

The week carried two distinct company-specific threads. On Monday the firm announced a broad US patent covering Rintatolimod (Ampligen®) used in combination with Pembrolizumab (Keytruda®), extending oncology IP protection for Ampligen through 2039. The stock spiked more than 28% intraday before paring gains to close up 4%. On Wednesday the company said it had significantly expanded Ampligen’s global patent estate, adding Long COVID protection across Europe and the UK through 2041. On Saturday it disclosed the issuance of 5,065,840 shares in an unregistered note exchange with Streeterville Capital.

## Analyst Ratings

Two brokers cover the stock: one rates it buy and one rates it overweight, with no hold, underweight or sell ratings. The consensus is buy, with a consensus target of $4.25, about 1767.3% above the latest close of $0.2276. Target prices range from $1.50 to $7.00, a wide spread. Within the biotechnology industry, the stock ranks 384th out of 507 names.

## The Week Ahead

No company earnings are scheduled for next week. US macro releases are concentrated on Thursday, including initial jobless claims, final demand PPI and existing home sales on an annualised basis. After the note exchange and share issuance this week, investors will be watching for any follow-through on share structure changes and further news on Ampligen’s development pipeline.

## In Short

The expanded patent estate gives Ampligen a longer protection window in oncology and Long COVID, and the consensus rating remains buy with a target far above spot. Yet the target range is unusually wide and only two brokers cover the name, pointing to deep disagreement on valuation. Equity dilution from the share issuance adds another layer of tension. The focus now shifts to how the new shares affect the free float and whether development or commercial milestones can support current valuation expectations.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)

## Related News & Research

- [AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of $5,070.276 in Common Shares](https://longbridge.com/en/news/305034899.md)
- [AIM ImmunoTech CEO and President Thomas K Equels Reports Acquisition of Common Shares Worth $3,166.644](https://longbridge.com/en/news/304681041.md)
- [AIM ImmunoTech Publishes Investor Presentation on Ampligen’s Potential in Pancreatic Cancer](https://longbridge.com/en/news/304471195.md)
- [The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.](https://longbridge.com/en/news/304985751.md)
- [US SEC seeks to close Musk, Tesla settlement fund](https://longbridge.com/en/news/305073867.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**